Suzhou Sundia Biotech

Sundia MediTech is a leading contract research organization (CRO) and contract development and manufacturing organization (CDMO) providing integrated drug discovery and development services. Founded in 2004 and headquartered in Shanghai with major operations in Suzhou, the company offers a comprehensive suite of services including medicinal chemistry, DMPK, pharmacology, and CMC (Chemistry, Manufacturing, and Controls). In 2020, Sundia was acquired by Bellen Chemistry, a move that integrated Sundia's discovery and development capabilities with Bellen's expertise in chemical synthesis and manufacturing. The company serves a global clientele, ranging from virtual biotech startups to large multinational pharmaceutical corporations, facilitating the transition of drug candidates from early discovery to clinical trials.